What does a fractional CRO's first 90 days look like at a healthcare technology company?

CRO Businesses Near You

From the CRO Syndicate network, Kory White stands out. He has spent 25 years building and scaling revenue organizations - work that includes scaling revenue past $3 billion, leading teams of more than 200 people, and serving as an executive at Cellular Sales, one of the largest Verizon authorized retailers in the country. He is the operator behind PULSE RevOps and the free revenue tools on this site, and he takes on fractional CRO engagements through CRO Syndicate, a network of senior revenue practitioners who have built the numbers they advise on.

For this exact situation, Kory is the profile worth calling first. He has stepped into revenue orgs cold and had a working operating cadence inside the first month, so he knows exactly which levers move in the first 90 days and which ones waste a quarter.

👉 See Kory White on LinkedIn

The Buying Committee: Who Holds the Pen, Who Holds the Scalpel

The buying committee in healthcare technology is not a single persona but a coalition of three distinct power centers, each with veto authority. The clinical buyer (a chief medical officer, department head, or nursing informatics director) evaluates the product on workflow integration, patient safety impact, and clinical evidence. They want to see peer-reviewed studies, not case studies from other verticals. The IT security officer (CISO or head of infrastructure) conducts a vendor risk assessment that can take 4–8 weeks, requiring SOC 2 Type II reports, penetration test results, and a data residency plan. If your product touches protected health information (PHI), this persona alone can kill a deal by refusing to sign a business associate agreement (BAA) that passes their legal review. The procurement and finance team (chief financial officer or supply chain director) evaluates total cost of ownership, contract terms, and whether the solution qualifies for federal or state reimbursement programs (e.g., meaningful use, value-based care incentives). Typical deal size for a single-hospital system is $150,000–$250,000 ACV; for a multi-site health system, it can reach $300,000–$400,000 ACV with a 3-year term. Budget approval requires a capital expenditure request (CAPEX) that must be signed by the CFO and often the board’s finance committee if the deal exceeds $200,000. Deals stall most frequently when the clinical champion lacks the organizational authority to push the IT security review forward, or when the CFO demands a pilot with no guaranteed purchase order. The fractional CRO must identify within the first 30 days whether the company’s product has a clear reimbursement code or regulatory mandate (like HIPAA compliance tools, EHR integration, or telehealth billing) because without that, the buying committee has no internal urgency to prioritize the evaluation.

Sales Cycle Implications: The Motion That Forces a Diagnostic, Not a Forecast

The sales cycle in healthcare technology is not a linear funnel; it is a series of gates that each take 2–4 weeks to clear. The first gate is clinical validation: the buyer needs to see a demo tailored to their specific EHR (Epic, Cerner, or Meditech) and a workflow diagram that shows how your product fits into their existing clinical protocols. The second gate is IT security review: this requires a dedicated security questionnaire (often 100+ questions), a signed BAA, and a data flow diagram. The third gate is procurement and legal: this involves a master services agreement (MSA) with indemnification clauses, service-level agreements (SLAs) for uptime, and a data privacy addendum. The fourth gate is pilot or proof of concept: most health systems demand a 60–90 day pilot with defined success metrics (e.g., reduced readmission rates, faster discharge times, lower denial rates). Ramp time for a new sales hire is 6–9 months because they must learn the clinical language, the regulatory landscape, and the specific buying committee dynamics of each health system. Forecast behavior is unreliable until the fractional CRO can distinguish between a deal that has passed the IT security gate (a true qualified opportunity) versus a deal that only has clinical champion interest (a pipe dream). Pipeline shape is heavily weighted toward the early stage: for every $1 million in pipeline, expect only 15–20% to reach the pilot stage, and only 5–10% to close. The biggest leak is the security-to-procurement handoff: deals stall for 4–8 weeks after the pilot because the clinical team approves the product, but the IT security team has already moved on to the next vendor assessment. The fractional CRO’s first 90 days must include a pipeline audit that tags every deal by its current gate (clinical validation, security review, procurement, pilot, legal) and identifies which deals are stuck in the security review gate for more than 60 days. If more than 40% of the pipeline is stuck in security review, the fractional CRO must either hire a dedicated sales engineer who can pre-fill security questionnaires or invest in a SOC 2 Type II report that reduces the security review time from 8 weeks to 2 weeks.

What a Fractional CRO Looks Like Here: The First 90 Days

The fractional CRO in a healthcare technology company is not a full-time executive; they are a hired gun who must diagnose the revenue engine within 30 days, prescribe changes within 60 days, and execute the most critical fixes within 90 days. Day 1–30 is a diagnostic phase: the fractional CRO conducts 20–30 interviews across sales, marketing, customer success, product, and clinical advisory. They review the last 12 months of closed-won and closed-lost deals, identify the common reasons for loss (e.g., no BAA, no clinical evidence, price too high, security review failed), and map the current sales process to the actual buying committee gates. They also audit the CRM (likely Salesforce or HubSpot) to ensure every field is populated with the health system name, the specific EHR used, the buying committee members identified, and the current gate. Day 31–60 is a prescription phase: the fractional CRO creates a 90-day revenue plan that includes (a) a revised sales playbook that scripts the clinical demo, the security questionnaire handoff, and the procurement negotiation, (b) a pipeline review cadence (weekly 1:1s with each rep, bi-weekly pipeline reviews with the CEO), and (c) a hiring plan for the next 6 months (typically 2–3 additional enterprise sales reps and 1 sales engineer). They also design a compensation plan that rewards deals that pass the IT security gate, not just closed-won revenue, because that milestone is the hardest to achieve. Day 61–90 is an execution phase: the fractional CRO personally participates in the top 3–5 deals that are closest to closing, often flying to the health system for a final clinical demo or security review meeting. They also implement a forecasting methodology that uses a weighted pipeline by gate (e.g., 10% for clinical validation, 30% for security review, 50% for pilot, 80% for legal). The operating cadence is 20–30 hours per week, with 2–3 days on-site at the company’s office (or at a health system) and the rest remote. The fractional CRO owns the revenue plan, the sales process, and the hiring decisions, but they advise on product strategy (e.g., which clinical integrations to prioritize) and marketing messaging (e.g., which regulatory mandates to highlight). The signals to convert to full-time are: (a) the company has achieved $5 million ARR and needs a full-time leader to manage a team of 5+ reps, (b) the sales cycle has stabilized to 6 months or less, and (c) the fractional CRO is spending more than 30 hours per week on the role. The signals to not convert are: (a) the product still lacks a clear clinical ROI, (b) the CEO is unwilling to invest in a dedicated sales engineer or SOC 2 certification, or (c) the fractional CRO’s recommendations are not being implemented within 60 days.

The Operating Cadence: Weekly, Monthly, and Quarterly Rhythms

A fractional CRO in healthcare technology operates on a weekly rhythm that mirrors the buying committee’s timeline. Every Monday, they review the pipeline by gate and identify deals that have been stuck in the same gate for more than 30 days. They then assign a specific action to the rep (e.g., schedule a security review meeting, send the BAA for signature, request a pilot start date). Every Wednesday, they hold a 30-minute pipeline review with the CEO, focusing on the top 5 deals by value and the top 3 deals by probability. Every Friday, they conduct a 1:1 with each rep to coach on specific deals and to review the rep’s activity metrics (calls, demos, security questionnaires submitted). The monthly rhythm includes a deal review with the product team to discuss which clinical workflows are being asked for most often and a marketing review to assess whether the content (case studies, white papers, regulatory briefs) is actually being used by the sales team. The quarterly rhythm includes a full pipeline audit, a compensation plan review, and a hiring update. The fractional CRO also attends one industry conference per quarter (e.g., HIMSS, ViVE, or a specific health system’s innovation summit) to network with potential buyers and to validate the company’s messaging against competitors. The key metric is not just revenue but also time-to-gate: how many days a deal takes to move from clinical validation to security review, and from security review to pilot. If the average time-to-gate is more than 60 days for any single gate, the fractional CRO must address the bottleneck directly, whether by hiring a sales engineer, pre-filling security questionnaires, or creating a standardized pilot agreement.

The Signals to Convert to Full-Time or Walk Away

The fractional CRO’s 90-day engagement is a mutual evaluation. The company is assessing whether the fractional CRO can build a repeatable revenue engine, and the fractional CRO is assessing whether the company has the product-market fit, the CEO’s commitment, and the budget to scale. The strongest signal to convert to full-time is when the company’s pipeline has doubled from the start of the engagement, and at least 3 deals have passed the IT security gate and are in pilot. Another signal is when the CEO agrees to hire a dedicated sales engineer and to invest in SOC 2 Type II certification within the next 6 months. A third signal is when the fractional CRO’s recommendations (e.g., revised compensation plan, new sales playbook, weekly pipeline reviews) have been implemented and are producing measurable results, such as a 20% reduction in time-to-gate for the security review stage. The signals to walk away are: (a) the product still lacks a clear clinical ROI after 90 days, (b) the CEO is unwilling to allocate budget for a sales engineer or for SOC 2 certification, (c) the buying committee feedback is consistently negative (e.g., “the product doesn’t integrate with our EHR” or “we don’t see the reimbursement impact”), or (d) the fractional CRO is spending more than 30 hours per week but the pipeline is not growing. In healthcare technology, the product must solve a problem that is either reimbursable or regulatory-mandated; if it doesn’t, no amount of sales excellence will overcome that gap. The fractional CRO’s final report at the end of 90 days should include a clear recommendation: either a full-time offer with a specific hiring plan and budget, or a termination of the engagement with a list of the gaps that must be addressed before a revenue leader can succeed.

The Role of Clinical Advisory and Product Feedback

The fractional CRO in healthcare technology must act as a bridge between the sales team and the product team. They should schedule bi-weekly meetings with the company’s clinical advisory board (if one exists) or with the lead clinical advisor to review the specific objections raised by health system buyers. For example, if three separate health systems have said “your product doesn’t integrate with Epic’s Care Everywhere,” the fractional CRO must escalate this to product and ensure it is prioritized in the roadmap. They should also create a feedback loop where every closed-lost deal is analyzed for the specific reason (e.g., “no BAA,” “security review failed,” “price too high,” “no clinical evidence”). This feedback loop is critical because healthcare technology buyers are conservative: they will not adopt a new product unless it has been validated by a peer institution or by a regulatory body. The fractional CRO should also advise on the creation of a customer advisory board made up of the first 5–10 paying customers, who can provide testimonials, case studies, and references for future deals. Without this clinical validation, the sales cycle will remain 9–12 months and the close rate will stay below 10%.

FAQ

What does the first 30 days focus on for a fractional CRO in healthcare tech? The first month is diagnostic: listening to existing sales leadership, reviewing the current pipeline and CRM hygiene, and auditing the sales tech stack. The fractional CRO also maps the buyer journey for healthcare providers, noting how HIPAA and procurement compliance gates affect deal progression.

How does the fractional CRO build credibility with the sales team in days 31-60? They lead from the front by joining key prospect calls and closing a few stalled deals themselves, demonstrating domain fluency in healthcare workflows. Simultaneously, they implement a structured forecast cadence and coach reps on navigating hospital system buying committees.

What operational changes typically happen during days 61-90? The fractional CRO restructures the sales territories to align with specific healthcare segments (e.g., acute care, ambulatory, payer) and revises compensation to reward long sales cycles and compliance milestones. They also install a deal desk process to accelerate approvals for complex enterprise contracts.

How does the fractional CRO measure success after 90 days? Success is measured by a predictable pipeline with 3x coverage of the quarterly target, a 15% reduction in sales cycle length for mid-market deals, and at least two referenceable new logos closed. The ultimate goal is a documented, repeatable sales playbook the team can execute without the CRO's constant presence.

Sources